CYTOMX THERAPEUTIC revenue breakdown overview

CYTOMX THERAPEUTIC revenue for the last year amounted to 125.43 M CHF, the most of which — 125.43 M CHF — came from its highest performing source at the moment, Probody Therapeutics, the year earlier bringing 85.22 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought CYTOMX THERAPEUTIC 125.43 M CHF, and the year before that — 85.22 M CHF.